MRI metrics as surrogate endpoints for EDSS progression in SPMS patients treated with IFN β-1b

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Neurology

• Publication date

  2003-05-13

• Fields of study

  Medicine

• Identifiers
  DOI 10.1212/01.WNL.0000063312.15758.B3PMID 12743232
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Placebo-controlled multicentre randomised trial of interferon (cid:1) -1b in treatment of secondary progressive multiple sclerosis

  2005cited by this paper
• Interferon beta-1b in secondary progressive MS

  2004cited by this paper
• MRI techniques to monitor MS evolution: The present and the future

  2002cited by this paper
• MRI metrics as surrogate markers for clinical relapse rate in relapsing-remitting MS patients

  2002cited by this paper
• The role of MRI as a surrogate outcome measure in multiple sclerosis

  2002cited by this paper
• Benefit of interferon &bgr;-1a on MSFC progression in secondary progressive MS

  2002cited by this paper
• Randomized controlled trial of interferon- beta-1a in secondary progressive MS

  2001cited by this paper
• Randomized controlled trial of interferon-beta-1a in secondary progressive MS

  2001cited by this paper
• Final analysis of the European multicenter trial on IFNβ-1b in secondary-progressive MS

  2001cited by this paper
• Clinical–MRI correlations in a European trial of interferon beta-1b in secondary progressive MS

  2001cited by this paper
• Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis. Meta-Analysis Group in Cancer.

  2000cited by this paper
• The validation of surrogate endpoints in meta-analyses of randomized experiments.

  2000cited by this paper
• Relapses and progression of disability in multiple sclerosis.

  2000cited by this paper
• Estimating the proportion of treatment effect explained by a surrogate marker by D. Y. Lin, T. R. Fleming and V. De Gruttola, Statistics in Medicine, 16, 1515–1527 (1997)

  1999cited by this paper
• Effect of interferon‐β1b on magnetic resonance imaging outcomes in secondary progressive multiple sclerosis: Results of a European multicenter, randomized, double‐blind, placebo‐controlled trial

  1999cited by this paper
• Modelling MRI enhancing lesion counts in multiple sclerosis using a negative binomial model: implications for clinical trials.

  1999cited by this paper
• Estimating the proportion of treatment effect explained by a surrogate marker.

  1999cited by this paper
• Magnetic resonance techniques to monitor disease evolution and treatment trial outcomes in multiple sclerosis.

  1999cited by this paper
• Effect of interferon-beta1b on magnetic resonance imaging outcomes in secondary progressive multiple sclerosis: results of a European multicenter, randomized, double-blind, placebo-controlled trial. European Study Group on Interferon-beta1b in secondary progressive multiple sclerosis.

  1999cited by this paper
• Guidelines for using quantitative measures of brain magnetic resonance imaging abnormalities in monitoring the treatment of multiple sclerosis

  1998cited by this paper
• Placebo-controlled multicentre randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosis

  1998cited by this paper
• Criteria for the validation of surrogate endpoints in randomized experiments.

  1998cited by this paper
• Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS.

  1998cited by this paper
• Estimating the proportion of treatment effect explained by a surrogate marker.

  1997cited by this paper
• Strategies for optimizing MRI techniques aimed at monitoring disease activity in multiple sclerosis treatment trials

  1997cited by this paper
• Improving interobserver variation in reporting gadolinium-enhanced MRI lesions in multiple sclerosis

  1997cited by this paper
• Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis

  1996cited by this paper
• Surrogate markers in AIDS and cancer trials.

  1995cited by this paper
• Surrogate markers in AIDS and cancer trials.

  1994cited by this paper
• Surrogate Markers in AIDS: Where Are We? Where Are We Going?

  1992cited by this paper
• Surrogate endpoints in clinical trials: definition and operational criteria.

  1989cited by this paper
• Serial gadolinium enhanced magnetic resonance imaging in multiple sclerosis.

  1988cited by this paper
• Rating neurologic impairment in multiple sclerosis

  1983cited by this paper

• Treating to target in multiple sclerosis: Do we know how to measure whether we hit it?

  2024cites this paper
• Hodnocení účinnosti léčby roztroušené sklerózy ve 21. století

  2019cites this paper
• Evaluation of multiple sclerosis treatment efficacy in 21st century

  2019cites this paper
• Disease activity impacts disability progression in primary progressive multiple sclerosis.

  2019cites this paper
• Peripapillary retinal nerve fibre layer thinning rate as a biomarker discriminating stable and progressing relapsing–remitting multiple sclerosis

  2019cites this paper
• Unraveling treatment response in multiple sclerosis

  2018cites this paper
• Predictive probability of success using surrogate endpoints

  2018cites this paper
• Single scan quantitative gradient recalled echo MRI for evaluation of tissue damage in lesions and normal appearing gray and white matter in multiple sclerosis

  2018cites this paper
• ‘No evidence of disease activity’ – is it an appropriate surrogate in multiple sclerosis?

  2018cites this paper
• Surrogate Markers in Multiple Sclerosis: The Role of Magnetic Resonance Imaging

  2016cites this paper
• Evaluating response to disease-modifying therapy in relapsing multiple sclerosis

  2015cites this paper
• Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis

  2014cites this paper
• Outcome Measures in Relapsing-Remitting Multiple Sclerosis: Capturing Disability and Disease Progression in Clinical Trials

  2014cites this paper
• Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis

  2014cites this paper
• Gradient echo magnetic resonance imaging correlates with clinical measures and allows visualization of veins within multiple sclerosis lesions

  2014cites this paper
• Magnetic resonance outcome measures in multiple sclerosis trials: time to rethink?

  2014cites this paper
• Defining and scoring response to IFN-β in multiple sclerosis

  2013cites this paper
• MRI as a surrogate marker for clinical outcomes in multiple sclerosis

  2013cites this paper
• Betaferon® – MRI-Daten

  2013cites this paper
• MRI lesions as a surrogate for relapses in multiple sclerosis: a meta-analysis of randomised trials.

  2013cites this paper
• Deficient MWF mapping in multiple sclerosis using 3D whole-brain multi-component relaxation MRI

  2012cites this paper
• MRI monitoring of immunomodulation in relapse-onset multiple sclerosis trials

  2012cites this paper
• On Nature of the Gradient Echo MR Signal and Its Application to Monitoring Multiple Sclerosis

  2012cites this paper
• Magnetic resonance active lesions as individual-level surrogate for relapses in multiple sclerosis

  2011influential citation
• A novel adaptive design strategy increases the efficiency of clinical trials in secondary progressive multiple sclerosis

  2011cites this paper
• Application of Interferon Beta-1b in Multiple Sclerosis

  2011cites this paper
• Short-Term Relapse Quantitation as a Fully Surrogate Endpoint for Long-Term Sustained Progression of Disability in RRMS Patients Treated with Natalizumab

  2011cites this paper
• Combined MRI lesions and relapses as a surrogate for disability in multiple sclerosis

  2011cites this paper
• MWFmapping in multiple sclerosis using 3 D whole-brain multi-component relaxation MRI

  2011cites this paper
• Disease-modifying therapy for multiple sclerosis in clinical practice

  2011cites this paper
• The long march to surrogates of meaningful clinical outcomes in MS trials

  2011cites this paper
• In vivo quantitative evaluation of brain tissue damage in multiple sclerosis using gradient echo plural contrast imaging technique

  2010cites this paper
• Surrogate endpoints for EDSS worsening in multiple sclerosis

  2010cites this paper
• MRI as an outcome in multiple sclerosis clinical trials.

  2009cites this paper
• Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: A meta‐analytic approach

  2009cites this paper
• MRI ASANOUTCOMEIN MULTIPLE SCLEROSIS CLINICAL TRIALS

  2009cites this paper
• MRI as an outcome in multiple sclerosis clinical trials

  2009cites this paper
• MRI ASANOUTCOMEIN MULTIPLE SCLEROSIS CLINICAL TRIALS

  2009cites this paper
• Magnetic resonance imaging metrics and their correlation with clinical outcomes in multiple sclerosis: a review of the literature and future perspectives

  2008cites this paper
• The use of MR imaging as an outcome measure in multiple sclerosis clinical trials.

  2008cites this paper
• Stellenwert der Magnetresonanztomographie für Diagnose, Verlaufskontrolle und Prognose der Multiplen Sklerose – Eine Literaturauswertung

  2008cites this paper
• Magnetic resonance imaging as a surrogate outcome for multiple sclerosis relapses

  2008cites this paper
• Statistical Issues Related to the Use of MRI Data in Multiple Sclerosis

  2007cites this paper
• Multiple Sclerosis and Demyelinating Diseases

  2007cites this paper
• Validation of MRI Surrogates

  2007cites this paper
• Interferon-β1b in multiple sclerosis

  2007cites this paper
• Secondary progressive multiple sclerosis: current knowledge and future challenges.

  2006cites this paper
• Long-term clinical outcome of primary progressive MS: Predictive value of clinical and MRI data

  2005cites this paper
• Interferon-β1b for multiple sclerosis

  2005cites this paper
• Application of hidden Markov models to multiple sclerosis lesion count data

  2005cites this paper
• Clinical drug evaluation using imaging readouts: regulatory perspectives.

  2005cites this paper
• The use of magnetic resonance imaging in multiple sclerosis: lessons learned from clinical trials

  2004cites this paper
• An update on neuroimaging of multiple sclerosis

  2004cites this paper
• Interferon-beta-1b: a review of its use in relapsing-remitting and secondary progressive multiple sclerosis.

  2004cites this paper
• Clinical and Imaging Parameters to Measure Disease Progression and Drug Efficacy in Multiple Sclerosis

  year unknowncites this paper